ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.105
AS - Asia 16.609
EU - Europa 9.114
SA - Sud America 2.405
AF - Africa 411
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 17
Totale 57.710
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.568
SG - Singapore 5.053
CN - Cina 3.315
HK - Hong Kong 3.003
VN - Vietnam 2.017
GB - Regno Unito 1.826
BR - Brasile 1.824
IT - Italia 1.604
FI - Finlandia 1.136
SE - Svezia 1.060
KR - Corea 713
RU - Federazione Russa 706
BD - Bangladesh 688
DE - Germania 626
FR - Francia 376
BG - Bulgaria 372
IN - India 355
PL - Polonia 354
CA - Canada 257
AR - Argentina 234
TR - Turchia 234
ID - Indonesia 226
NL - Olanda 172
UA - Ucraina 170
JP - Giappone 159
MX - Messico 153
ZA - Sudafrica 148
IQ - Iraq 144
AE - Emirati Arabi Uniti 122
ES - Italia 119
AT - Austria 106
LT - Lituania 76
PK - Pakistan 75
EC - Ecuador 74
IE - Irlanda 74
CO - Colombia 73
EG - Egitto 59
CL - Cile 54
SA - Arabia Saudita 54
MA - Marocco 53
UZ - Uzbekistan 51
CZ - Repubblica Ceca 50
PH - Filippine 46
VE - Venezuela 45
BE - Belgio 39
MY - Malesia 39
JO - Giordania 37
DZ - Algeria 36
PY - Paraguay 36
RO - Romania 36
AU - Australia 33
TN - Tunisia 31
KZ - Kazakistan 28
CR - Costa Rica 27
IL - Israele 26
PE - Perù 26
KE - Kenya 24
AZ - Azerbaigian 23
NP - Nepal 23
TH - Thailandia 22
CH - Svizzera 21
AL - Albania 20
ET - Etiopia 20
UY - Uruguay 20
IR - Iran 19
GR - Grecia 18
BO - Bolivia 17
NO - Norvegia 17
DO - Repubblica Dominicana 16
KG - Kirghizistan 15
A2 - ???statistics.table.value.countryCode.A2??? 14
PT - Portogallo 14
TW - Taiwan 14
DK - Danimarca 13
HN - Honduras 13
JM - Giamaica 13
NZ - Nuova Zelanda 13
OM - Oman 13
RS - Serbia 13
LB - Libano 12
MK - Macedonia 12
BH - Bahrain 11
GE - Georgia 11
MD - Moldavia 11
PR - Porto Rico 11
LV - Lettonia 10
QA - Qatar 10
EE - Estonia 9
HU - Ungheria 9
BY - Bielorussia 8
CY - Cipro 7
HR - Croazia 7
KH - Cambogia 7
SK - Slovacchia (Repubblica Slovacca) 7
BA - Bosnia-Erzegovina 6
GT - Guatemala 6
LA - Repubblica Popolare Democratica del Laos 6
NI - Nicaragua 6
PA - Panama 6
PS - Palestinian Territory 6
Totale 57.591
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.508
Ashburn 3.424
Singapore 3.254
Hong Kong 2.963
Fairfield 2.373
Chandler 2.080
Helsinki 1.087
London 988
New York 975
San Jose 865
Nyköping 857
Woodbridge 848
Houston 795
Wilmington 755
Hefei 701
Seattle 700
Ho Chi Minh City 639
Los Angeles 634
Cambridge 626
Beijing 601
Seoul 588
The Dalles 565
Hanoi 502
Council Bluffs 493
Chicago 490
Ann Arbor 475
San Diego 470
Princeton 372
Sofia 359
Southend 344
Warsaw 335
Milan 258
Buffalo 226
Moscow 221
Orem 212
Shanghai 194
Salt Lake City 188
Modena 183
Jersey City 179
São Paulo 172
Jakarta 154
Dearborn 152
Jacksonville 152
Dallas 150
Tokyo 118
Redondo Beach 113
Da Nang 110
Istanbul 104
Porto Alegre 97
Frankfurt am Main 93
Phoenix 92
Lauterbourg 89
Haiphong 87
Bremen 86
Chennai 86
Johannesburg 86
Bupyeong-gu 84
Rome 81
Piscataway 80
Atlanta 77
Denver 76
Tampa 73
Secaucus 69
Dublin 68
Toronto 68
Munich 66
Vienna 66
Bologna 65
Elk Grove Village 65
Brooklyn 64
San Francisco 63
Amsterdam 59
Montreal 58
Newark 58
Norwalk 57
North Bergen 56
Mexico City 54
Rio de Janeiro 54
Miano 52
Nuremberg 52
Stockholm 51
Viroflay 51
Manchester 49
Paris 49
Guangzhou 48
Izmir 48
Baghdad 45
Kent 44
Kilburn 44
Tashkent 44
Augusta 43
Biên Hòa 43
Des Moines 43
Mumbai 43
Boardman 41
Charlotte 41
Detroit 41
Dhaka 41
Grafing 41
Sterling 41
Totale 39.724
Salva come PNG Salva come JPEG
Nome #
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 534
Non-alcoholic steatohepatitis and liver transplantation 522
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 385
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 381
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 360
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 349
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 331
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 325
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 320
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 314
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 310
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 309
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 305
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 301
From current status to optimization of HCV treatment: Recommendations from an expert panel 294
Missed treatment in an Italian HBV infected patients cohort: HBV RER 294
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 292
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 286
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 279
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 270
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 269
Global multi-stakeholder endorsement of the MAFLD definition 263
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 261
Treatment of nonalcoholic steatohepatitis in adults: present and future 258
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 258
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 256
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 253
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 248
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 247
Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients 240
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 240
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 237
Adaptive response in Hepatitis B virus infection 236
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 235
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 235
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 234
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 234
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 231
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 227
Characteristics of hepatocellular carcinoma in Italy 225
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 222
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study 219
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 218
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 217
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 217
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 217
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 215
Update on Alcohol and Viral Hepatitis 212
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 212
Adherence to Mediterranean diet in liver transplant recipients: a cross-sectional multicenter study 210
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 210
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 210
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 209
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 208
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 206
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 206
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 203
CD 133+ stem cells for the treatment of end stage liver disease 203
Gross pathologic types of hepatocellular carcinoma in Italy. 202
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 202
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study 201
Alcohol and viral hepatitis: a mini-review 201
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 200
Clinical and serological profile of primary biliary cirrhosis in men 200
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 200
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 200
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 200
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 198
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 198
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 198
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 197
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 197
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 195
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 195
Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study 194
Chronic hepatitis B: Are we close to a cure? 194
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 193
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 193
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis 187
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 187
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 186
Familial intrahepatic cholestasis: New and wide perspectives 185
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 185
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 184
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation 183
Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy 181
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 181
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 181
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants 180
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 180
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 179
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 179
Comparing and combining gamma-hydroxybutiric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study 179
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned 178
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 178
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis 178
Indomethacin increases 2′,5′-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis 177
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 177
A review on extrahepatic manifestations of chronic hepatitis c virus infection and the impact of direct-acting antiviral therapy 177
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 175
Totale 23.397
Salva come PNG Salva come JPEG
Categoria #
all - tutte 297.085
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 297.085
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021136 0 0 0 0 0 0 0 0 0 0 0 136
2021/20225.712 823 485 224 244 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/202512.345 463 84 65 962 2.405 1.716 518 929 1.506 944 1.111 1.642
2025/202625.625 1.254 771 1.909 2.610 3.282 2.815 3.028 1.652 2.575 2.524 2.528 677
Totale 58.231